Βιβλιογραφική ενημέρωση / EULAR 2016 update

Slides:



Advertisements
Similar presentations
Downloaded from 1 Alendronate vs. Risedronate Comparison Trial.
Advertisements

1Stopeck A et al. Proc SABCS 2010;Abstract P
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.
Design: A randomized, prospective, double-blind cohort followed for 16 weeks RenehaVis Original Study 50 DMW 50 HMW 50 LMW 50 Placebo.
Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.
Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :
A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.
1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.
Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
Efectivness of Spa Therapy in Severe Knee Osteoarthritis; Randomize Controlled Trial Mine Karagülle,MD Istanbul, Turkey.
Perspectives on Clinical Outcomes of Studies of Products for Use in Cartilage Repair Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of.
Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):
 Exercise and Vitamin D in Fall Prevention Among Older Women Journal Club, June 2016 Theresa Drallmeier and Tu Dao.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
An Alternative to Data Imputation in Analgesic Clinical Trials David Petullo, Thomas Permutt, Feng Li Division of Biometrics II, Office of Biostatistics.
Geisler C et al. Proc ASH 2011;Abstract 290.
Nephrology Journal Club The SPRINT Trial Parker Gregg
The SPRINT Research Group
a randomized controlled trial
Pearson correlation coefficient, r
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
Attal M et al. Proc ASH 2010;Abstract 310.
On behalf of The MTN-020/ASPIRE Study Team
Alcohol, Other Drugs, and Health: Current Evidence
MONOCLONAL ANTIBODIES AGAINST NERVE GROWTH FACTOR IN PAIN MANAGENT
Alcohol, Other Drugs, and Health: Current Evidence
HOPE: Heart Outcomes Prevention Evaluation study
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
PMA Analysis of the CREST Trial Approvability of the RX Acculink Carotid Stent System for Revascularization of Carotid Artery Stenosis in Standard Surgical.
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Protocol U Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF.
EXPERIMENTAL STUDIES.
Methods Subjects: yo w migraine wwo aura (defined by ICHD3beta) for at least 1yr ≥4 and
Randomized Clinical Trial Jeffrey G. Gross, M.D. for the DRCR Network
NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial  R. Leighton, C. Åkermark,
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Barrios C et al. SABCS 2009;Abstract 46.
Section III: Neurohormonal strategies in heart failure
Krop I et al. SABCS 2009;Abstract 5090.
Bergh J et al. SABCS 2009;Abstract 23.
Section 7: Aggressive vs moderate approach to lipid lowering
FX006 Pivotal Ph 2b Data September , 2015
Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial  Y.Y. Leung,
LRC-CPPT and MRFIT Content Points:
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Outcomes in SCS Trials Ali Rezai MD.
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis 
Comparison of INSTI vs EFV
Switch to RAL-containing regimen
A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee  T.J. Schnitzer, J.A. Marks  Osteoarthritis.
The efficacy and safety of omalizumab in pediatric allergic asthma
The Research Question Knee osteoarthritis (OA) is common, debilitating and often refractory to routine care. Prolotherapy, a “regenerative” injection.
Prompt PRP vs. Ranibizumab + Deferred PRP for PDR Study
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Fig. 2. Efficacy endpoints among treatment groups: least square (LS) mean changes from baseline in the WOMAC-pain subscale (A), total WOMACOA index score.
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

Βιβλιογραφική ενημέρωση / EULAR 2016 update ΝΙΚΟΛΑΟΣ ΚΟΥΓΚΑΣ ΕΠΙΚ.ΕΠΙΜΕΛΗΤΗΣ Β ΡΕΥΜΑΤΟΛΟΓΙΚΗΣ ΚΛΙΝΙΚΗΣ ΠΑΓΝΗ

Osteoporosis Osteoarthritis Abaloparatide Romosozumab Long term use of aledronate Osteoarthritis Fulranumab chondroitin sulfate and glucosamine sulfate Ultrasound and hand OA

OBJECTIVE-DESIGN To determine the efficacy and safety of abaloparatide, 80μg, vs placebo for prevention of new vertebral fracture in postmenopausal women at risk of osteoporotic fracture Phase 3, double-blind, RCT Postmenopausal women with (BMD) T score −2.5 and >−5.0 at the lumbar spine or femoral neck and radiological evidence >2 mild or >1 moderate lumbar or thoracic vertebral fracture or history of low- trauma nonvertebral fracture within the past 5 years.Women (>65 y) with fracture criteria and a T score −2.0 and >−5.0 or without fracture criteria and a T score −3.0 and >−5.0 could enroll

INTERVENTIONS -OUTCOMES Blinded, daily s.c. injections of placebo(n=821); abaloparatide, 80 μg (n = 824); or open-label teriparatide, 20 μg (n=818) for 18 months Primary end point: percentage of participants with new vertebral fracture in the abaloparatide vs placebo groups Secondary end points: change in BMD at total hip, femoral neck, and lumbar spine in abaloparatide-treated vs placebo participants

RESULTS BMD increases were greater with abaloparatide than placebo (all P < .001)

CONCLUSION Subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months

OBJECTIVE-DESIGN To evaluate the effects of 1 year of romosozumab (a monoclonal antibody that binds sclerostin ) treatment on the risk of fracture among women with postmenopausal osteoporosis Phase 3 trial double-blind, placebo-controlled, parallel-group trial 7180 postmenopausal women who had a T score of –2.5 to –3.5 at the total hip or femoral neck and up to 2 moderate vertebral fractures

INTERVENTIONS -OUTCOMES Patients randomly assigned to receive s.c. injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months, at a dose of 60 mg, administered s.c. every 6 months Primary end point: the cumulative incidence of new vertebral fractures at 12 months and 24 months. Secondary end points: clinical (a composite of nonvertebral and symptomatic vertebral) and nonvertebral fractures

RESULTS 12 MONTHS 24 MONTHS new vertebral fractures in 16/3321 patients (0.5%) in the romosozumab group, and 59/3322 (1.8%) in the placebo group (representing a 73% lower risk with romosozumab; P<0.001) Clinical fractures in 58/3589 patients (1.6%) in the romosozumab group and 90/3591 (2.5%) in the placebo group (a 36% lower risk with romosozumab; P=0.008) Nonvertebral fractures in 56/3589 patients (1.6%) in the romosozumab group and in 75/3591 (2.1%) in the placebo group (P=0.10) vertebral fractures were significantly lower in the romosozumab group than in the placebo group after each group made the transition to denosumab (0.6% [21 of 3325 patients] in the romosozumab group vs. 2.5% [84 of 3327] in the placebo group, a 75% lower risk with romosozumab; P<0.001)

CONCLUSION In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months

OBJECTIVE-DESIGN To determine the skeletal safety and efficacy of long term (≥10 years) alendronate use in patients with osteoporosis Open register based cohort study

INTERVENTIONS -OUTCOMES Treatment with alendronate Incident fracture of the subtrochanteric femur or femoral shaft (ST/FS) or the hip. Non-fracture controls from the cohort were matched to fracture cases by sex, year of birth, and year of initiation of alendronate treatment

RESULTS 1428 participants sustained a ST/FS (incidence rate 3.4/1000 person years, 95% confidence interval 3.2 to 3.6), and 6784 a hip fracture (16.2/1000 person years, 15.8 to 16.6). The risk of ST/FS was lower with high adherence to treatment with alendronate (medication possession ratio (MPR, a proxy for compliance) >80%) compared with poor adherence (MPR <50%; odds ratio 0.88, 0.77 to 0.99; P=0.05). The risk was no higher in long term users (≥10 dose years; 0.70, 0.44 to 1.11; P=0.13) or in current compared with past users (0.91, 0.79 to 1.06; P=0.22). Similarly, MPR >80% was associated with a decreased risk of hip fracture (0.73, 0.68 to 0.78; P<0.001) as was longer term cumulative use for 5-10 dose years (0.74, 0.67 to 0.83; P<0.001) or ≥10 dose years (0.74, 0.56 to 0.97; P=0.03).

CONCLUSION Long term adherent use of alendronate in excess of 10 dose years was associated with an adjusted 30% lower risk of hip fracture and no increase in the risk of fractures of the subtrochanteric femur or femoral shaft

Long-term Safety and Efficacy of Fulranumab in Patients with Moderate-to-Severe Osteoarthritis Pain: A Randomized, Double-blind, Placebo-controlled Study

OBJECTIVE-DESIGN To evaluate long-term safety and efficacy of fulranumab (a human anti-nerve growth factor (NGF) monoclonal antibody) in patients with moderate-to-severe chronic osteoarthritis (OA) knee or hip pain Placebo-controlled, phase-2 double-blind (DB) extension study Patients aged 40 to 80 years, with OA of hip or knee, on stable regimens of NSAIDs, and/or opioids, entering DB phase with a mean OA pain intensity score of ≥5, averaged over the last 3 days of pain scores before randomization using an 11-point numerical rating scale (NRS)

INTERVENTIONS -OUTCOMES Patients were equally randomized to 1mgQ4wk, 3mgQ8wk, 3mgQ4wk, 6mgQ8wk, or10mgQ8wk fulranumab (s.c.) or placebo in the 12-week DB efficacy phase, and completing this DB efficacy phase, were eligible to continue the dose throughout a 92-week extension phase followed by a 24- week post treatment follow-up (PFTU) Safety assessments included evaluation of treatment-emergent adverse events (TEAEs), pre- identified AEs of interest and joint replacements. Efficacy included change from baseline to end of DB extension phase in Patient Global Assessment, Western Ontario and McMaster Universities Osteoarthritis Index pain, and physical function subscale scores.

RESULTS Long-term sustained improvements were observed in all efficacy parameters following fulranumab treatment (1mgQ4wk, 3mgQ4wk, 10mgQ8wk) versus placebo. Similar percentage of patients in both groups experienced TEAEs (placebo: 88%; fulranumab: 91%; all phases). Across all fulranumab groups, arthralgia (21%) and OA (18%) were most common TEAEs; most common serious TEAEs were knee (10%) and hip (7%) arthroplasty, with 80% occurring during PTFU. Neurologic-related TEAEs (25%, all phases) were generally mild-to-moderate

CONCLUSION Long-term fulranumab treatment was generally well-tolerated and efficacious for patients with hip and knee OA Dosing every 4 weeks is preferred as it showed a better long-term efficacy profile than dosing every 8 weeks.

Chondroitin sulfate plus glucosamine sulfate shows no superiority over placebo in a randomized, double-blind, placebo-controlled clinical trial in patients with knee osteoarthritis

OBJECTIVE-DESIGN To assess the efficacy and safety of chondroitin sulfate (CS) plus glucosamine sulfate (GS) compared to placebo in patients with symptomatic knee osteoarthritis (KOA) multicenter, randomized, double-blinded, placebo-controlled study 164 patients with Kellgren-Lawrence stages II-III KOA and moderate to severe pain (VAS: 62.1±11.3 mm)

INTERVENTIONS -OUTCOMES Patients were randomized to receive either CS (1200 mg) plus GS (1500 mg) or placebo in a single oral daily dose for 6 months. primary endpoint: the mean change in VAS global pain Secondary outcomes included the mean change in the investigator global assessment, total WOMAC, pain and function subscales of WOMAC, OMERACT-OARSI 2004 responder rate, and rescue medication use. Adverse events were also recorded

RESULTS CS+GS was inferior to placebo in reduction of joint pain for the modified intention-to-treat (mITT) population [11.8±2.4 mm (19%) vs 20.5±2.4 mm (33%); ∆= -8.7; -14.2%; p<0.03], but not for per-protocol completers Placebo and CS+GS similarly improved total WOMAC, as well as pain and function WOMAC subscales in both mITT population and per- protocol completers. Neither the OMERACT-OARSI responder rate nor the use of rescue medication differed between both groups. Severe adverse events were uncommon and equally distributed.

CONCLUSION CS+GS failed to demonstrate superiority over placebo in reducing pain and function impairment in patients with symptomatic KOA at 6 months

OBJECTIVE-DESIGN To examine whether ultrasound predicts radiographic hand osteoarthritis (OA) progression after 5 years. Participants from the Oslo Hand OA cohort

INTERVENTIONS -OUTCOMES Ultrasound examination (gray-scale (GS) synovitis and power Doppler (PD) signals) at baseline and conventional radiographs and clinical examination at baseline and 5-year follow-up Radiographic progression was defined as an increase in global OA according to the Kellgren–Lawrence (KL) scale or progression of individual radiographic OA features Whether baseline ultrasound features and clinical examination predicted radiographic progression

RESULTS Radiographic progression occurred in 17.9% joints for KL, 12.1% for joint space narrowing, 11.7% for osteophytes and 4.5% for erosions. Ultrasound- detected inflammation predicted KL progression, and dose–response associations were observed for GS synovitis grade 1 (OR=2.8, 95% CI 1.8 to 4.2), grade 2 (OR=3.6, 95% CI 2.2 to 5.8) and grade 3 (OR=15.2, 95% CI 6.9 to 33.6), and for PD signal grade 1 (OR=2.9, 95% CI 1.2 to 6.8) and grades 2–3 (OR=12.0, 95% CI 3.5 to 41.0)

CONCLUSION Ultrasound-detected GS synovitis and PD signals were significantly associated with radiographic progression after 5 years. Ultrasound could be a useful tooll to detect patients with hand OA who are likely to progress